quinoxalines has been researched along with Bladder Cancer in 28 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (3.57) | 29.6817 |
| 2010's | 4 (14.29) | 24.3611 |
| 2020's | 23 (82.14) | 2.80 |
| Authors | Studies |
|---|---|
| Claiborne, RT; Tsan, GL | 1 |
| Avadhani, A; De Porre, P; Dosne, AG; Goeyvaerts, N; Li, LY; O'Hagan, A; Ouellet, D; Perez Ruixo, JJ; Valade, E | 1 |
| Akapame, S; Burgess, EF; Duran, I; Fleming, MT; García-Donas, J; Huddart, RA; Joshi, M; Loriot, Y; Mellado, B; Monga, M; Necchi, A; O'Hagan, A; Park, SH; Rezazadeh Kalebasty, A; Santiago-Walker, AE; Siefker-Radtke, AO; Tagawa, ST; Varlamov, S; Zakharia, Y | 1 |
| Loriot, Y; Siefker-Radtke, AO | 1 |
| Hu, C; Hu, X; Shang, X; Zhao, Y; Zheng, T | 1 |
| Cosmai, L; Franza, A; Giannatempo, P; Pirovano, M | 1 |
| Belal, F; El-Enany, N; Elawady, T; Khedr, A | 1 |
| Bellmunt, J; Montazeri, K | 1 |
| Baur, EM; Gschwend, JE; Hindupur, SV; Holm, PS; Horn, T; Koch, JA; Nawroth, R; Schmid, SC; Slotta-Huspenina, J; Wang, D; Youssef, A | 1 |
| Kolesar, JM; Myint, ZW; Roubal, K | 1 |
| Lebenthal, J; Nauseef, JT; Tagawa, ST; Villamar, DM; Vlachostergios, PJ | 1 |
| Carles, J; González, M; Maldonado, X; Mateo, J; Morales-Barrera, R; Morote, J; Raventos, C; Serra, E; Suárez, C; Valverde, C | 1 |
| Galsky, MD; Patel, V; Qin, Q | 1 |
| Amir, M; Javed, S; Qureshi, MA | 1 |
| Ertl, IE; Ilijazi, D; Loriot, Y; Mostafaei, H; Shariat, SF | 1 |
| Bagby, S; Bortoletti, C; D'Angelo, A; Galli, IC; Roviello, G | 1 |
| Bednova, O; Leyton, JV | 1 |
| Montazeri, K; Sonpavde, G | 1 |
| Bansal, P; Dwivedi, DK; Goyal, S; Gupta, V; Hatwal, D; Maithani, M; Sharma, P | 1 |
| Al-Obaidy, KI; Cheng, L | 1 |
| Alberts, AR; Iflé, IG; Scholtes, MP; van der Veldt, AAM; Verhagen, PCMS; Zuiverloon, TCM | 1 |
| Hubert, P; Loriot, Y; Selmani, Z; Thiery-Vuillemin, A | 1 |
| Kim, HS; Seo, HK | 1 |
| Alvarez, JD; Bahleda, R; Bell, K; Cardona, GM; Gaffney, D; Karkera, JD; King, P; Lorenzi, MV; Luo, FR; Moy, CH; Platero, SJ; Portale, JC; Santiago-Walker, A; Sharp, M | 1 |
| Bétrian, S; Delord, JP; Gomez-Roca, C; Sibaud, V; Vigarios, E | 1 |
| He, S; Li, X; Martin, DT; Tian, Y; Weiss, RM | 1 |
| Bastaros, JM; Carles, J; de Castro, AM; Maldonado, X; Morales-Barrera, R; Morote, J; Racca, F; Suárez, C; Valverde, C | 1 |
| Archer, CL; Haas, GP; Jones, RF; Morse, P; Shirai, T; Wang, CY | 1 |
15 review(s) available for quinoxalines and Bladder Cancer
| Article | Year |
|---|---|
Erdafitinib in locally advanced/metastatic urothelial carcinoma with certain
Topics: Carcinoma, Transitional Cell; Humans; Protein Kinase Inhibitors; Pyrazoles; Quinoxalines; Urinary Bladder Neoplasms | 2022 |
Erdafitinib for the treatment of metastatic bladder cancer.
Topics: Animals; Carcinoma, Transitional Cell; Humans; Neoplasm Metastasis; Protein Kinase Inhibitors; Pyrazoles; Quinoxalines; Receptor, Fibroblast Growth Factor, Type 2; Receptor, Fibroblast Growth Factor, Type 3; Urinary Bladder Neoplasms | 2020 |
Erdafitinib: A novel therapy for FGFR-mutated urothelial cancer.
Topics: Antineoplastic Agents; Carcinoma, Transitional Cell; Humans; Progression-Free Survival; Protein Kinase Inhibitors; Pyrazoles; Quinoxalines; Receptor, Fibroblast Growth Factor, Type 2; Receptor, Fibroblast Growth Factor, Type 3; Urinary Bladder Neoplasms | 2020 |
An evaluation of the efficacy and safety of erdafitinib for the treatment of bladder cancer.
Topics: Antineoplastic Agents; Clinical Trials, Phase II as Topic; Humans; Molecular Targeted Therapy; Pyrazoles; Quinoxalines; Receptors, Fibroblast Growth Factor; Treatment Outcome; Urinary Bladder Neoplasms | 2020 |
The future of bladder cancer therapy: Optimizing the inhibition of the fibroblast growth factor receptor.
Topics: Antineoplastic Agents; Humans; Neoplasm Metastasis; Pyrazoles; Quinoxalines; Randomized Controlled Trials as Topic; Receptors, Fibroblast Growth Factor; Urinary Bladder Neoplasms | 2020 |
Urothelial carcinoma: the development of FGFR inhibitors in combination with immune checkpoint inhibitors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Drug Development; Humans; Immune Checkpoint Inhibitors; Protein Kinase Inhibitors; Pyrazoles; Quinoxalines; Receptor, Fibroblast Growth Factor, Type 3; Signal Transduction; Urinary Bladder Neoplasms | 2020 |
Fibroblast growth factor receptors across urothelial carcinoma landscape.
Topics: Antineoplastic Agents; Carcinoma, Transitional Cell; Humans; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Pyrazoles; Quinoxalines; Receptor, Fibroblast Growth Factor, Type 3; Receptors, Fibroblast Growth Factor; Treatment Outcome; Urinary Bladder Neoplasms; Urologic Neoplasms | 2020 |
Overview of the clinical use of erdafitinib as a treatment option for the metastatic urothelial carcinoma: where do we stand.
Topics: Administration, Oral; Adult; Antineoplastic Agents; Apoptosis; Carcinoma, Transitional Cell; Disease Progression; Humans; Protein Kinase Inhibitors; Pyrazoles; Quinoxalines; Urinary Bladder Neoplasms | 2020 |
Targeted Molecular Therapeutics for Bladder Cancer-A New Option beyond the Mixed Fortunes of Immune Checkpoint Inhibitors?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antigens, Neoplasm; B7-H1 Antigen; Camptothecin; Cell Adhesion Molecules; Gene Expression Regulation, Neoplastic; Humans; Immune Checkpoint Inhibitors; Immunoconjugates; Immunotherapy; Lymphatic Metastasis; Molecular Targeted Therapy; Programmed Cell Death 1 Receptor; Pyrazoles; Quinoxalines; Urinary Bladder; Urinary Bladder Neoplasms | 2020 |
Salvage systemic therapy for metastatic urothelial carcinoma: an unmet clinical need.
Topics: Antibodies, Monoclonal; Biomarkers, Tumor; Carcinoma, Transitional Cell; Humans; Immune Checkpoint Inhibitors; Molecular Targeted Therapy; Neoplasm Metastasis; Pyrazoles; Quinoxalines; Salvage Therapy; Survival Rate; Urinary Bladder Neoplasms | 2021 |
Erdafitinib as a Novel and Advanced Treatment Strategy of Metastatic Urothelial Carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Transitional Cell; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Pyrazoles; Quinoxalines; Receptor, Fibroblast Growth Factor, Type 3; Urinary Bladder Neoplasms | 2021 |
Fibroblast growth factor receptor (
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma; Exons; Gene Amplification; Gene Fusion; Genetic Predisposition to Disease; Humans; Molecular Targeted Therapy; Mutation, Missense; Phenotype; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Pyrroles; Quinoxalines; Receptor, Fibroblast Growth Factor, Type 3; Thiophenes; Urinary Bladder Neoplasms; Urothelium | 2021 |
Biomarker-Oriented Therapy in Bladder and Renal Cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; B7-H1 Antigen; Biomarkers, Tumor; Carcinoma, Renal Cell; Cisplatin; Gene Expression Regulation, Neoplastic; Humans; Immune Checkpoint Inhibitors; Kidney Neoplasms; Lymphatic Metastasis; Mutation; Protein Kinase Inhibitors; Pyrazoles; Quinoxalines; Receptor, Fibroblast Growth Factor, Type 2; Receptor, Fibroblast Growth Factor, Type 3; Recurrence; Urinary Bladder Neoplasms | 2021 |
Emerging treatments for bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Antineoplastic Agents; BCG Vaccine; Carcinoma, Transitional Cell; Clinical Trials as Topic; Genes, Viral; Genetic Therapy; Humans; Hyperthermia; Immune Checkpoint Inhibitors; Immunoconjugates; Organ Sparing Treatments; Photochemotherapy; Pyrazoles; Quinoxalines; Retreatment; Treatment Failure; Urinary Bladder Neoplasms | 2021 |
Targeting fibroblast growth factor receptors and immune checkpoint inhibitors for the treatment of advanced bladder cancer: New direction and New Hope.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Transitional Cell; Humans; Ipilimumab; Nivolumab; Phenylurea Compounds; Piperazines; Pyrazoles; Pyridines; Pyrimidines; Quinolines; Quinoxalines; Receptors, Fibroblast Growth Factor; Urinary Bladder Neoplasms | 2016 |
2 trial(s) available for quinoxalines and Bladder Cancer
| Article | Year |
|---|---|
Exposure-response analyses of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma.
Topics: Aged; Carcinoma, Transitional Cell; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Progression-Free Survival; Protein Kinase Inhibitors; Pyrazoles; Quinoxalines; Receptors, Fibroblast Growth Factor; Survival Rate; Urinary Bladder Neoplasms | 2022 |
Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study.
Topics: Aged; Carcinoma, Transitional Cell; Central Serous Chorioretinopathy; ErbB Receptors; Follow-Up Studies; Humans; Middle Aged; Mutation; Neoplasm Metastasis; Pyrazoles; Quinoxalines; Urinary Bladder Neoplasms | 2022 |
11 other study(ies) available for quinoxalines and Bladder Cancer
| Article | Year |
|---|---|
Case Report: Erdafitinib-induced Central Serous Chorioretinopathy.
Topics: Aged, 80 and over; Carcinoma, Transitional Cell; Central Serous Chorioretinopathy; Female; Humans; Male; Protein Kinase Inhibitors; Pyrazoles; Quality of Life; Quinoxalines; Receptors, Fibroblast Growth Factor; United States; Urinary Bladder Neoplasms | 2022 |
Erdafitinib for locally advanced or metastatic urothelial carcinoma.
Topics: Carcinoma, Transitional Cell; Humans; Protein Kinase Inhibitors; Pyrazoles; Quinoxalines; Urinary Bladder Neoplasms | 2022 |
Ipatasertib (GDC-0068) and erdafitinib co-treatment for inducing mitochondrial apoptosis through Bim upregulation in bladder cancer cells.
Topics: Apoptosis; Bcl-2-Like Protein 11; Humans; Mitochondria; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazoles; Pyrimidines; Quinoxalines; Receptors, Fibroblast Growth Factor; Up-Regulation; Urinary Bladder Neoplasms | 2022 |
Utility of Kolliphor RH 40 in micellar sensitized fluorescence of the novel tyrosine kinase inhibitor "Erdafitinib": Application to human plasma.
Topics: Carcinoma, Transitional Cell; Humans; Micelles; Protein Kinase Inhibitors; Pyrazoles; Quinoxalines; Solvents; Spectrometry, Fluorescence; Urinary Bladder Neoplasms | 2022 |
STAT3/5 Inhibitors Suppress Proliferation in Bladder Cancer and Enhance Oncolytic Adenovirus Therapy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Chick Embryo; Combined Modality Therapy; Cyclic S-Oxides; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Humans; Hydroxybenzoates; Janus Kinases; Nitriles; Nitrofurans; Oncolytic Virotherapy; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Quinoxalines; STAT3 Transcription Factor; STAT6 Transcription Factor; Urinary Bladder Neoplasms | 2020 |
Biomolecular interactions and binding dynamics of tyrosine kinase inhibitor erdafitinib, with human serum albumin.
Topics: Binding Sites; Carcinoma, Transitional Cell; Circular Dichroism; Humans; Molecular Docking Simulation; Protein Binding; Protein Kinase Inhibitors; Pyrazoles; Quinoxalines; Serum Albumin, Human; Spectrometry, Fluorescence; Thermodynamics; Tumor Microenvironment; Urinary Bladder Neoplasms | 2021 |
FGFR alterations in urothelial carcinoma: Picking the right target.
Topics: Carcinoma, Transitional Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Gene Fusion; Humans; Molecular Targeted Therapy; Morpholines; Mutation; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Pyrroles; Quinoxalines; Receptor, Fibroblast Growth Factor, Type 2; Receptor, Fibroblast Growth Factor, Type 3; Thiophenes; Urinary Bladder Neoplasms | 2021 |
Oncogenic Characterization and Pharmacologic Sensitivity of Activating Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations to the Selective FGFR Inhibitor Erdafitinib.
Topics: Animals; Biomarkers, Tumor; Male; Oncogene Proteins, Fusion; Oncogenes; Pyrazoles; Quinoxalines; Rats, Nude; Receptors, Fibroblast Growth Factor; Tomography, X-Ray Computed; Urinary Bladder Neoplasms | 2017 |
Severe Onycholysis and Eyelash Trichomegaly Following Use of New Selective Pan-FGFR Inhibitors.
Topics: Eyelashes; Eyelid Diseases; Fibroblast Growth Factors; Glioblastoma; Humans; Male; Middle Aged; Onycholysis; Pyrazoles; Quinoxalines; Severity of Illness Index; Urinary Bladder Neoplasms | 2017 |
Synergistic inhibition of GP130 and ERK signaling blocks chemoresistant bladder cancer cell growth.
Topics: Butadienes; Carcinoma, Transitional Cell; Cell Line, Tumor; Cell Movement; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Glycoproteins; Humans; Hydrazines; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 1; Nitriles; Quinoxalines; Urinary Bladder Neoplasms | 2019 |
Carcinogenicity of the N-hydroxy derivative of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine, 2-amino-3, 8-dimethyl-imidazo[4,5-f]quinoxaline and 3, 2'-dimethyl-4-aminobiphenyl in the rat.
Topics: Aminobiphenyl Compounds; Animals; Animals, Newborn; Body Weight; Carcinogens; Carcinoma, Transitional Cell; Colonic Neoplasms; Hyperplasia; Imidazoles; Male; Mutagens; Prostatic Neoplasms; Pyridines; Quinoxalines; Rats; Rats, Inbred ACI; Urinary Bladder Neoplasms | 2000 |